Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.
复制标题

DOI:
10.1038/mtm.2016.61
复制
发表时间:
2016
期刊:
Molecular therapy. Methods & clinical development
影响因子:
--
通讯作者:
--
中科院分区:
其他
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

我们正在开发一种泛进化枝HIV-1 T细胞疫苗HIVconsv,它可以补充Env疫苗的预防作用,并成为治愈HIV的关键。我们的策略将疫苗引起的效应T细胞集中在HIV-1蛋白质组的功能和结构保守区域(不是全长蛋白质,不仅是表位),这些区域是大多数全球变体所共有的,如果突变,会导致复制适应性丧失。我们在牛津的低风险HIV-1阴性成人中的第一个临床试验证明了这样的原理,即当从全长蛋白/病毒的背景中取出并通过涉及猿腺病毒和痘病毒修饰的安卡拉牛痘病毒的组合的有效方案递送时,天然的大多数次显性表位可以诱导具有广泛特异性和功能的稳健的CD 8 + T细胞,其能够抑制体外HIV-1复制。在这里,我们第一次在非洲的低风险HIV-1阴性成年人中测试了这种策略。我们发现,疫苗耐受性良好,并诱导高频率的广泛HIV-特异性多功能T细胞,其在体外抑制来自四个主要分支A、B、C和D的病毒。由于撒哈拉以南非洲是全球受HIV-1/AIDS影响最严重的地区,因此试验HIV-CORE 004代表了对这种高度合理和有前途的疫苗策略进行有效性评价的重要阶段。
We are developing a pan-clade HIV-1 T-cell vaccine HIVconsv, which could complement Env vaccines for prophylaxis and be a key to HIV cure. Our strategy focuses vaccine-elicited effector T-cells on functionally and structurally conserved regions (not full-length proteins and not only epitopes) of the HIV-1 proteome, which are common to most global variants and which, if mutated, cause a replicative fitness loss. Our first clinical trial in low risk HIV-1-negative adults in Oxford demonstrated the principle that naturally mostly subdominant epitopes, when taken out of the context of full-length proteins/virus and delivered by potent regimens involving combinations of simian adenovirus and poxvirus modified vaccinia virus Ankara, can induce robust CD8+ T cells of broad specificities and functions capable of inhibiting in vitro HIV-1 replication. Here and for the first time, we tested this strategy in low risk HIV-1-negative adults in Africa. We showed that the vaccines were well tolerated and induced high frequencies of broadly HIVconsv-specific plurifunctional T cells, which inhibited in vitro viruses from four major clades A, B, C, and D. Because sub-Saharan Africa is globally the region most affected by HIV-1/AIDS, trial HIV-CORE 004 represents an important stage in the path toward efficacy evaluation of this highly rational and promising vaccine strategy.
DOI: 10.1126/science.1254031
发表时间: 2014-07-11
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Carlson JM;Schaefer M;Monaco DC;Batorsky R;Claiborne DT;Prince J;Deymier MJ;Ende ZS;Klatt NR;DeZiel CE;Lin TH;Peng J;Seese AM;Shapiro R;Frater J;Ndung'u T;Tang J;Goepfert P;Gilmour J;Price MA;Kilembe W;Heckerman D;Goulder PJ;Allen TM;Allen S;Hunter E
通讯作者: Hunter E
DOI: 10.1016/j.immuni.2012.11.022
发表时间: 2013-03-21
期刊: Immunity
影响因子: 32.4
作者:
Ferguson AL;Mann JK;Omarjee S;Ndung'u T;Walker BD;Chakraborty AK
通讯作者: Chakraborty AK
DOI: 10.1016/j.vaccine.2015.12.021
发表时间: 2016-02-24
期刊: Vaccine
影响因子: 5.5
作者:
Ahmed T;Borthwick NJ;Gilmour J;Hayes P;Dorrell L;Hanke T
通讯作者: Hanke T
DOI: 10.1084/jem.20070784
发表时间: 2007-10-01
期刊: The Journal of experimental medicine
影响因子: --
作者:
Almeida JR;Price DA;Papagno L;Arkoub ZA;Sauce D;Bornstein E;Asher TE;Samri A;Schnuriger A;Theodorou I;Costagliola D;Rouzioux C;Agut H;Marcelin AG;Douek D;Autran B;Appay V
通讯作者: Appay V
DOI: 10.1182/blood-2006-07-037481
发表时间: 2007-06-01
期刊: BLOOD
影响因子: 20.3
作者:
Fujiwara, Mamoru;Takiguchi, Masafumi
通讯作者: Takiguchi, Masafumi